Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary r-MedSci.cn

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary r

Geyer, CE; Huang, CS; Mano, MS; Loibl, S; Mamounas, EP; Untch, M; Wolmark, N; Rastogi, P; Fischer, HH; Redondo, A; Jackisch, C; Jacot, W; Conlin, AK; Schneeweiss, A; Wapnir, IL; Fasching, PA; DiGiovanna, MP; Wuelfing, P; Arce-Salinas, C; Crown, JP; S

CANCER RESEARCH, 2019; 79 (4):

科室
- - 订阅+
  - 更多科室
工具
服务